The levels of immunosuppressive checkpoint protein PD‐L1 and tumor‐infiltrating lymphocytes were integrated to reveal the glioma tumor microenvironment

In spite of significant strides in the realm of cancer biology and therapeutic interventions, the clinical prognosis for patients afflicted with glioblastoma (GBM) remains distressingly dismal. The tumor immune microenvironment (TIME), a crucial player in the progression, treatment response, and prognostic trajectory of glioma, warrants thorough exploration. Within this intricate microcosm, the immunosuppressive checkpoint protein PD‐L1 and tumor‐infiltrating lymphocytes (TILs) emerge as pivotal constituents, underscoring their potential role in deciphering glioma biology and informing treatment strategies. However, prognostic models based on the association between PD‐L1 expression and TIL infiltration in the tumor immune microenvironment have not been established. The aim of this study was to explore TIME genes associated with PD‐L1 expression and TIL invasion and to construct a risk score for predicting the overall survival (OS) of GBM patients based on these genes. The samples were separately classified according to the PD‐L1 expression level and TIL score and TIME‐related genes were identified using differential expression and weighted gene co‐expression network analysis. The DEGs were subjected to least absolute contraction and selection operator (LASSO) ‐Cox regression to construct TIME associated risk score (TIMErisk). A TIMErisk was developed based on STEAP3 and CXCL13 genes. The STLEAP3 was demonstrated to be involved in glioma progression. The results showed that the patients in the high TIMErisk group had poor OS compared with subjects in the low TIMErisk group. The biological phenotypes associated with TIMErisk were analyzed in terms of functional enrichment, tumor immune profile, and tumor mutation profile. The results on tumor immune dysfunction and exclusion dysfunction (TIDE) score and immune surface score (IPS) showed that GBM patients with different TIME risks had different responses to immunotherapy. Tumor purity analysis indicated that PD‐L1 and TIL scores were positively correlated with TIMErisk score and negatively correlated with tumor purity. These results show that the TIMErisk‐based prognostic model had high predictive value for the prognosis and immune characteristics of GBM patients. Immunohistochemical staining images of patients in the high and low TIMErisk groups were analyzed, showing that the degree of immune cell infiltration was higher in the high TIMErisk group relative to the low TIMErisk group. The present study provides a basis for understanding glioma tumor microenvironment and a foundation for conducting comprehensive immunogenomic analysis.

[1]  Cheng Yan,et al.  System analysis based on the cuproptosis-related genes identifies LIPT1 as a novel therapy target for liver hepatocellular carcinoma , 2022, Journal of Translational Medicine.

[2]  Wenqi Wu,et al.  Allicin suppressed Escherichia coli-induced urinary tract infections by a novel MALT1/NF-κB pathway. , 2022, Food & function.

[3]  Wenqi Wu,et al.  Dissecting and Evaluating the Therapeutic Targets of Coptis Chinensis Franch in the Treatment of Urinary Tract Infections Induced by Escherichia coli , 2022, Frontiers in Pharmacology.

[4]  Lei Wang,et al.  STEAP3 Affects Ferroptosis and Progression of Renal Cell Carcinoma Through the p53/xCT Pathway , 2022, Technology in cancer research & treatment.

[5]  Yufei Liu,et al.  Radiogenomics Map Reveals the Landscape of m6A Methylation Modification Pattern in Bladder Cancer , 2021, Frontiers in Immunology.

[6]  Zhifei Wang,et al.  Prospects of antibodies targeting CD47 or CD24 in the treatment of glioblastoma , 2021, CNS neuroscience & therapeutics.

[7]  H. Daldrup-Link,et al.  Glioblastoma Multiforme (GBM): An overview of current therapies and mechanisms of resistance. , 2021, Pharmacological research.

[8]  Di Wu,et al.  An Autophagy-Related Gene Signature Associated With Clinical Prognosis and Immune Microenvironment in Gliomas , 2020, Frontiers in Oncology.

[9]  M. Lou,et al.  Prognosis Analysis and Validation of m6A Signature and Tumor Immune Microenvironment in Glioma , 2020, Frontiers in Oncology.

[10]  Qin Xu,et al.  Remodeling tumor immune microenvironment (TIME) for glioma therapy using multi-targeting liposomal codelivery , 2020, Journal for ImmunoTherapy of Cancer.

[11]  Junnian Zheng,et al.  Turning Cold into Hot: Firing up the Tumor Microenvironment. , 2020, Trends in cancer.

[12]  Wanzun Lin,et al.  Characterization of Hypoxia Signature to Evaluate the Tumor Immune Microenvironment and Predict Prognosis in Glioma Groups , 2020, Frontiers in Oncology.

[13]  Zhixiong Liu,et al.  Novel insights into astrocyte-mediated signaling of proliferation, invasion and tumor immune microenvironment in glioblastoma. , 2020, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[14]  B. Neyns,et al.  Understanding the glioblastoma immune microenvironment as basis for the development of new immunotherapeutic strategies , 2020, eLife.

[15]  Hao Zhang,et al.  Glioblastoma Treatment Modalities besides Surgery , 2019, Journal of Cancer.

[16]  M. Kazanietz,et al.  CXCL13 and Its Receptor CXCR5 in Cancer: Inflammation, Immune Response, and Beyond , 2019, Front. Endocrinol..

[17]  D. Adah,et al.  CXCL13/CXCR5 signaling axis in cancer. , 2019, Life sciences.

[18]  S. Wong,et al.  Targeting immune cells for cancer therapy , 2019, Redox biology.

[19]  J. Castle,et al.  Actively personalized vaccination trial for newly diagnosed glioblastoma , 2018, Nature.

[20]  Y. Chu,et al.  The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy , 2018, Journal of Neuroinflammation.

[21]  T. Jiang,et al.  Molecular and clinical characterization of IDH associated immune signature in lower-grade gliomas , 2018, Oncoimmunology.

[22]  Jindong Chen,et al.  Immune Checkpoint in Glioblastoma: Promising and Challenging , 2017, Front. Pharmacol..

[23]  G. Wolf,et al.  Telltale tumor infiltrating lymphocytes (TIL) in oral, head & neck cancer. , 2016, Oral oncology.

[24]  Yu Wang,et al.  CGCG clinical practice guidelines for the management of adult diffuse gliomas. , 2016, Cancer letters.

[25]  G. Reifenberger,et al.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary , 2016, Acta Neuropathologica.

[26]  J. Sosman,et al.  Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma , 2016, Cell.

[27]  Baolan Li,et al.  Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer , 2015, Scientific Reports.

[28]  M. Santarpia,et al.  Tumor immune microenvironment characterization and response to anti-PD-1 therapy , 2015, Cancer biology & medicine.

[29]  K. Tomczak,et al.  The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge , 2015, Contemporary oncology.

[30]  N. Hacohen,et al.  Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity , 2015, Cell.

[31]  Hiroshi Yamamoto,et al.  RAGE expression in tumor-associated macrophages promotes angiogenesis in glioma. , 2014, Cancer research.

[32]  Paul Geeleher,et al.  pRRophetic: An R Package for Prediction of Clinical Chemotherapeutic Response from Tumor Gene Expression Levels , 2014, PloS one.

[33]  Zhixiong Liu,et al.  p38γ overexpression in gliomas and its role in proliferation and apoptosis , 2013, Scientific Reports.

[34]  Vincent J. Lynch,et al.  Measurement of mRNA abundance using RNA-seq data: RPKM measure is inconsistent among samples , 2012, Theory in Biosciences.

[35]  K. Akashi,et al.  Human STEAP3 maintains tumor growth under hypoferric condition. , 2011, Experimental cell research.

[36]  Susan M. Chang,et al.  Recent advances in therapy for glioblastoma. , 2010, Archives of neurology.

[37]  R. Mirimanoff,et al.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. , 2009, The Lancet. Oncology.

[38]  B. Scheithauer,et al.  The 2007 WHO Classification of Tumours of the Central Nervous System , 2007, Acta Neuropathologica.

[39]  S. Horvath,et al.  Analysis of oncogenic signaling networks in glioblastoma identifies ASPM as a molecular target , 2006, Proceedings of the National Academy of Sciences.

[40]  K. Kamiya,et al.  Midkine Plays a Protective Role Against Cardiac Ischemia/Reperfusion Injury Through a Reduction of Apoptotic Reaction , 2006, Circulation.

[41]  Isabelle Camby,et al.  Present and potential future issues in glioblastoma treatment , 2006, Expert review of anticancer therapy.

[42]  A. Brandes,et al.  Adjuvant chemotherapy in the treatment of high grade gliomas. , 2005, Cancer treatment reviews.

[43]  Martin J. van den Bent,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[44]  Jason G. Cyster,et al.  A B-cell-homing chemokine made in lymphoid follicles activates Burkitt's lymphoma receptor-1 , 1998, Nature.

[45]  S. Rosenberg,et al.  A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. , 1986, Science.

[46]  W. Curry,et al.  Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human glioma. , 2007, Cancer immunity.

[47]  Y. Leea,et al.  Analysis of oncogenic signaling networks in glioblastoma identifies ASPM as a molecular target , 2006 .